CD44 and head and neck squamous cell carcinoma: While CD44 plays an emerging role in HNSCC prognostication, the development of an anti-CD44 immunoconjugate bivatuzumab mertansine for therapeutic use in patients with advanced HNSCC was terminated after the immunoconjugate resulted in skin toxicity [40].